Page last updated: 2024-10-20

thymine and Lung Neoplasms

thymine has been researched along with Lung Neoplasms in 21 studies

Lung Neoplasms: Tumors or cancer of the LUNG.

Research Excerpts

ExcerptRelevanceReference
"The possibility of interstitial pneumonitis should always be considered when a patient develops a fever and respiratory disorder during treatment containing TAS-102."1.48[A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer]. ( Hiramatsu, M; Imai, Y; Kobayashi, T; Kono, E; Sakane, J; Suzuki, Y; Tsunematsu, I, 2018)

Research

Studies (21)

TimeframeStudies, this research(%)All Research%
pre-19905 (23.81)18.7374
1990's6 (28.57)18.2507
2000's3 (14.29)29.6817
2010's7 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Unseld, M1
Drimmel, M1
Siebenhüner, A1
Gleiss, A1
Bianconi, D1
Kieler, M1
Scheithauer, W1
Winder, T1
Prager, GW1
Kono, E1
Hiramatsu, M1
Kobayashi, T1
Tsunematsu, I1
Imai, Y1
Sakane, J1
Suzuki, Y1
Lee, SJ1
Yeo, JS1
Lee, HJ1
Lee, EJ1
Kim, SY1
Jang, SJ1
Lee, JJ1
Ryu, JS1
Moon, DH1
Gao, P1
Zhao, H1
You, J1
Jing, F1
Hu, Y1
Hasegawa, J1
Noura, S1
Hirota, M1
Matsumura, T1
Yasuyama, A1
Takata, A1
Koga, C1
Murakami, M1
Kameda, C1
Oda, N1
Kawabata, R1
Morishima, H1
Shimizu, J1
Matsunami, N1
Saito, T1
Mitomi, H1
Izumi, H1
Suehara, Y1
Okubo, T1
Torigoe, T1
Takagi, T1
Kaneko, K1
Sato, K1
Matsumoto, T1
Yao, T1
Zheng, X1
Duan, W1
Xu, J1
Nie, C1
Yang, Z1
Wang, H1
Wang, W1
Lu, D1
Rodin, SN1
Rodin, AS1
Cohen, Y1
Xing, M1
Mambo, E1
Guo, Z1
Wu, G1
Trink, B1
Beller, U1
Westra, WH1
Ladenson, PW1
Sidransky, D1
ROGERS, S1
Wang, YJ1
Ho, YS1
Lo, MJ1
Lin, JK1
Ronai, ZA1
Gradia, S1
Peterson, LA1
Hecht, SS1
Matsuda, A1
Dan, A1
Minakawa, N1
Tregear, SJ1
Okazaki, S1
Sugimoto, Y1
Sasaki, T1
Shields, AF1
Mankoff, D1
Graham, MM1
Zheng, M1
Kozawa, SM1
Link, JM1
Krohn, KA1
Chen, H1
Lum, A1
Seifried, A1
Wilkens, LR1
Le Marchand, L1
Hainaut, P1
Pfeifer, GP1
Devereux, TR1
Anderson, MW1
Belinsky, SA1
Wolberg, WH1
Dvorák, O1
Elis, J1
Perlík, F1
Kvícalová, M1
Jandová, A1
Skoda, V1
Kafka, V1
Platonova, GM1
Pogosiants, EE1
Kaye, AM1
Trainin, N1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors With Biologic and Proteomic Analysis[NCT00095459]Phase 157 participants (Actual)Interventional2004-11-02Completed
A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer[NCT00436215]Phase 255 participants (Actual)Interventional2006-12-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Number of Participants With Adverse Events

Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00436215)
Timeframe: up to 28 months

InterventionParticipants (Count of Participants)
BAY 43-9006 + Bevacizumab54

Progression-free Survival

Progression free survival is defined by the number of weeks between the first day of treatment and the date of cancer progression. (NCT00436215)
Timeframe: up to 28 months

InterventionWeeks (Mean)
BAY 43-9006 + Bevacizumab26

Clinical Response Rate.

Clinical response rate is defined as the percentage of participants with a complete response (CR) or partial response (PR) per the Response Evaluation Criteria in Solid Tumors (RECIST). CR is disappearance of all target lesions. PR is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. Progressive disease (PD) is a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable disease (SD) is neither sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started lasting at least 6 months. (NCT00436215)
Timeframe: patients were followed for a median of 18 weeks (range 1-116 weeks)

Interventionpercentage of participants (Number)
Complete ResponsePartial ResponseProgressive DiseaseStable Disease
BAY 43-9006 + Bevacizumab0192160

Reviews

1 review available for thymine and Lung Neoplasms

ArticleYear
Association between interleukin-8 -251A/T polymorphism and risk of lung cancer: a meta-analysis.
    Cancer investigation, 2014, Volume: 32, Issue:10

    Topics: Adenine; Asian People; Computational Biology; Databases, Bibliographic; Genetic Association Studies;

2014

Trials

1 trial available for thymine and Lung Neoplasms

ArticleYear
A controlled clinical trial with the cytostatic agent thyminalkylamine and its fluorinated derivative on advanced ovarian tumours.
    Neoplasma, 1971, Volume: 18, Issue:4

    Topics: Alkylating Agents; Female; Fluorine; Hemodynamics; Humans; Leukocyte Count; Leukocytes; Lung Neoplas

1971

Other Studies

19 other studies available for thymine and Lung Neoplasms

ArticleYear
Optimizing Treatment Sequence for Late-line Metastatic Colorectal Cancer Patients Using Trifluridine/Tipiracil and Regorafenib.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule;

2018
[A Case of Interstitial Pneumonitis Induced by TAS-102 for Liver and Lung Metastasis of Colorectal Cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:9

    Topics: Aged; Drug Combinations; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male;

2018
Thymidine phosphorylase influences [(18)F]fluorothymidine uptake in cancer cells and patients with non-small cell lung cancer.
    European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:7

    Topics: Adult; Aged; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dideoxynucleosi

2014
[A Case of Metastatic Colorectal Cancer Refractory to Standard Chemotherapies Treated with TAS-102 with Bevacizumab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Combined Modality Therapy; Drug Combina

2016
A case of secondary malignant giant-cell tumor of bone with p53 mutation after long-term follow-up.
    Human pathology, 2011, Volume: 42, Issue:5

    Topics: Adenocarcinoma; Arthrography; Base Sequence; Cell Transformation, Neoplastic; Cysteine; Femur; Fibro

2011
Functionally significant nicotine acetylcholine receptor subunit α5 promoter haplotypes are associated with susceptibility to lung cancer in Chinese.
    Cancer, 2011, Oct-15, Volume: 117, Issue:20

    Topics: Adult; Aged; Asian People; Case-Control Studies; China; Cytosine; Female; Gene Deletion; Gene Freque

2011
On the origin of p53 G:C --> T:A transversions in lung cancers.
    Mutation research, 2002, Oct-31, Volume: 508, Issue:1-2

    Topics: Adenine; Chi-Square Distribution; Databases, Genetic; DNA Repair; Gene Frequency; Humans; Lung Neopl

2002
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
BRAF mutation in papillary thyroid carcinoma.
    Journal of the National Cancer Institute, 2003, Apr-16, Volume: 95, Issue:8

    Topics: Adenine; Carcinoma, Papillary; Case-Control Studies; Head and Neck Neoplasms; Humans; Lung Neoplasms

2003
Studies of the mechanism of action of urethane in initiating pulmonary adenomas in mice. II. Its relation to nucleic acid synthesis.
    The Journal of experimental medicine, 1957, Apr-01, Volume: 105, Issue:4

    Topics: Adenine; Adenoma; Animals; DNA; Lung Neoplasms; Mice; Neoplasms; Nucleic Acids; Orotic Acid; Pyrimid

1957
Oxidative modification of DNA bases in rat liver and lung during chemical carcinogenesis and aging.
    Chemico-biological interactions, 1995, Volume: 94, Issue:2

    Topics: 2-Acetylaminofluorene; Adenine; Aging; Animals; Antineoplastic Agents; Disease Models, Animal; DNA D

1995
G to A transitions and G to T transversions in codon 12 of the Ki-ras oncogene isolated from mouse lung tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related DNA methylating and pyridyloxobutylating agents.
    Carcinogenesis, 1993, Volume: 14, Issue:11

    Topics: Adenine; Animals; Base Sequence; Carcinogens; Codon; Dimethylnitrosamine; DNA, Neoplasm; Female; Gen

1993
Nucleosides and nucleotides. 123. Synthesis of 1-(2-deoxy-2-isocyano-beta-D-arabinofuranosyl)cytosine and related nucleosides as potential antitumor agents.
    Journal of medicinal chemistry, 1993, Dec-24, Volume: 36, Issue:26

    Topics: Animals; Antineoplastic Agents; Cytarabine; Deoxycytidine; Drug Stability; Humans; Isocyanates; Leuk

1993
Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 1996, Volume: 37, Issue:2

    Topics: Carbon Dioxide; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Humans; Lung Neoplasms;

1996
Association of the NAD(P)H:quinone oxidoreductase 609C-->T polymorphism with a decreased lung cancer risk.
    Cancer research, 1999, Jul-01, Volume: 59, Issue:13

    Topics: Alleles; Asian People; Case-Control Studies; Cytosine; Female; Genetic Variation; Genotype; Hawaii;

1999
Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke.
    Carcinogenesis, 2001, Volume: 22, Issue:3

    Topics: Case-Control Studies; Codon; DNA Damage; Guanine; Humans; Lung Neoplasms; Mutagens; Nicotiana; Plant

2001
Role of ras protooncogene activation in the formation of spontaneous and nitrosamine-induced lung tumors in the resistant C3H mouse.
    Carcinogenesis, 1991, Volume: 12, Issue:2

    Topics: Animals; Base Sequence; Codon; Dimethylnitrosamine; DNA; Drug Resistance; Gene Expression Regulation

1991
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
    Cancer research, 1972, Volume: 32, Issue:1

    Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem

1972
[The effect of thymine on the development of adenomain the lungs of mice under the influence of urethane and N-hydroxyurethane].
    Voprosy onkologii, 1969, Volume: 15, Issue:2

    Topics: Adenoma; Animals; Lung Neoplasms; Mice; Neoplasms, Experimental; Thymine; Urethane

1969
Urethan carcinogenesis and nucleic acid metabolism: factors influencing lung adenoma induction.
    Cancer research, 1966, Volume: 26, Issue:10

    Topics: Aminopterin; Animals; Lung Neoplasms; Mice; Neoplasms, Experimental; Nucleic Acids; Orotic Acid; Thy

1966